Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the RAT: Evidence for pharmacokinetic interactions

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 123-133

  Napoli, Kimberly L ^a   Wang, Mou Er ^a   Stepkowski, Stanislaw M ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Concentration; Cyclosporine; Distribution; Rat; Sirolimus

Indexed keywords

CYCLOSPORIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; DATA ANALYSIS; DOSE RESPONSE; DRUG ACTIVITY; FLUORESCENCE POLARIZATION IMMUNOASSAY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TISSUE DISTRIBUTION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG INTERACTIONS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; KIDNEY; LIVER; LUNG; MALE; MUSCLES; MYOCARDIUM; POLYENES; RATS; RATS, WISTAR; SIROLIMUS; SPLEEN; TESTIS; TISSUE DISTRIBUTION;

EID: 0031958040     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00001     Document Type: Article

References (45)

1. Kronbach T, Fischer V, Meyer U. Cyclosporine metabolism in human liver: identification of a cytochrome CYP3 gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43: 630-5.
2. Sattler M, Guengerich F, Yun C-H, Christians U, Sewing K-Fr. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992;20:753-61.
3. Christians U, Sattler M, Schiebel H, et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab Dispos 1992;20:186-91.
4. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
5. Yacyshyn B, Bowen-Yacyshyn M, Pilarski L. Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. Scand J Immunol 1996;43:449-55.
6. Hedayati S, Bernareggi A, Rowland M. Absorption of cyclosporin in the rat. J Pharm Pharmacol 1991;43:122-4.
7. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992;33: 39-43.
8. Vickers S, Fisher V, Connors S, et al. Cyclosporin A metabolism in human liver, kidney, and intestinal slices: comparison to rat and dog slices and human cell lines. Drug Metab Dispos 1992;20: 802-9.
9. Follath F, Wenk M, Vozeh S, et al. Intravenous cyclosporin kinetics in renal failure. Clin Pharmacol Ther 1983;34:638-43.
10. Neiderberger W, Lemaire M, Maurer G, et al. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983;15(suppl 1):2419-21.
11. Maurer G. Metabolism of cyclosporine. Transplant Proc 1985;17 (suppl 1):19-26.
12. Wagner O, Schreiber E, Heitz F, Maurer G. Tissue distribution, disposition, and metabolism of cyclosporine in rats. Drug Metab Dispos 1987;15:377-83.
13. Atkinson K, Boland J, Britton K, Biggs J. Blood and tissue distribution of cyclosporin in humans and mice. Transplant Proc 1983; 15:2430-3.
14. Ried M, Gibbons S, Kwok D, et al. Cyclosporin levels in human tissues of patients treated for one week to one year. Transplant Proc 1983;15:2434-7.
15. Bernareggi A, Rowland M. Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinetics and Biopharmaceutics 1991;19:21-50.
16. Wacher V, Liu T, Roberts J, et al. Time course of cyclosporine and its metabolites in blood, liver and spleen of naive Lewis rats: comparison with preliminary data obtained in transplanted animals. Biopharm Drug Dispos 1995;16:303-12.
17. Hebert M, Roberts J, Prueksaritanont T, Benet L. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
18. Kolars J, Schmiedin-Ren P, Schuetz J, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
19. Gomez D, Wacher V, Tomlanovich S, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
20. Yee G. Pharmacokinetic interactions between cyclosporine and other drugs. Transplant Proc 1990;22:1203-7.
21. Bauer S, Brockmüller J, Kewitz H, Roots I. The effect of the new immunosuppressive drug FK506 on the formation of secondary metabolites of cyclosporin A. Int J Clin Pharmacol Ther Tox 1992; 30:540-2.
22. Sattler M, Guengerich F, Yun C-H, et al. Cytochrome P-450 enzymes are responsible for biotransformation of FK506 and rapamycin in rat and man. Drug Metab Dispos 1992;20:753-61.
23. Streit F, Christians U, Schiebel H-M, et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/ MS after incubation with human liver microsomes. Drug Metab Dispos 1996;24:1272-8.
24. Whiting P, Woo J, Adam B, et al. Toxicity of rapamycin: a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat. Transplantation 1991;52:203-8.
25. Stepkowski SM, Tian L, Napoli KL, et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 1997;108:63-8.
26. Stepkowski S, Napoli K, Wang M-E, et al. The effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996;62:986-94.
27. Napoli K, Wang M-E, Stepkowski S, Kahan B. Distribution of sirolimus in rat tissue. Clin Biochem 1997;30:135-42.
28. Napoli K, Chan W, Wang M-E. An appropriate statistical approach for the comparison of FPIA to HPLC for determination of cyclosporine concentrations in animal tissues. J Clin Ligand Assay 1996;19:190-7.
29. Shargel L, Yu A. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norwalk, CT: Appleton and Lange, 1993;494.
30. Lensmeyer G, Wiebe D, Carlson I. Deposition of nine metabolites of cyclosporine in human tissues, bile, urine and whole blood. Transplant Proc 1988;20(suppl 2):614-22.
31. Lindberg-Freijs A, Karlsson M. Dose dependent absorption and linear disposition of cyclosporin A in rat. Biopharmaceutics Drug Dispos 1994;15:75-85.
32. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986;28(suppl 5):9-15.
33. Wood A, Maurer G, Niederberger W, Beveridge T. Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 1983;15(suppl 1):2409-12.
34. Ryffel B. Cyclosporine binding proteins Identification, distribution, function and relation to FK binding proteins. Biochem Pharmacol 1993;46:1-12.
35. Galat A. Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem 1993;216:689-707.
36. Ryffel B, Woerly G, Greiner B, et al. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunol 1991;72:399-404.
37. Marks W, Harding M, Handschumacher R, et al. The immunochemical distribution of cyclophilin in normal mammalian tissues. Transplantation 1991;52:340-5.
38. Ryffel B, Foxwell BMJ, Mihatsch MJ, et al. Biologic significance of cyclosporine metabolites. Transplant Proc 1988;20(suppl 2): 575-84.
39. Murgia M, Jordan S, Kahan B. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996;49:209-16.
40. Aszalos A. Immunosuppressive agents as modulators of MDR in cancer: preclinical studies. In: Lieberman R, Mukherjee A, eds. Principles of Drug Development and Autoimmunity. Austin:RG Landes, 1996: 741-7.
41. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine A in the blood. J Pharm Pharmacol 1982;34:715-8.
42. Annesley TM, Giacherio DA, Feldkamp CS. Cyclosporine distribution in blood: concomitant effect of hematocrit, concentration of metabolites and temperature. J Clin Immunoassay 1987;10:226-31.
43. Yatscoff RW, LeGatt D, Keenan R, Chackowsky P. Blood distribution of rapamycin. Transplantation 1993;56:1202-6.
44. Galat A. Peptidylproline cis-trans isomerases: immunophilins. Eur J Biochem 1993;216:689-707.
45. Dumont FJ, Kastner C, Iacovine F Jr, Fischer PA. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. J Pharmacol Exper Ther 1994;268:32-41.